Teva Pharms Company Profile

What is the competitive landscape for TEVA PHARMS, and when can generic versions of TEVA PHARMS drugs launch?

TEVA PHARMS has three hundred and eighteen approved drugs.

There are two US patents protecting TEVA PHARMS drugs. There are forty-four tentative approvals on TEVA PHARMS drugs.

There are seventeen patent family members on TEVA PHARMS drugs in twelve countries and nine hundred and sixteen supplementary protection certificates in eighteen countries.

Summary for Teva Pharms

International Patents:	17
US Patents:	2
Tradenames:	264
Ingredients:	259
NDAs:	318

Drugs and US Patents for Teva Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms	VARDENAFIL HYDROCHLORIDE	vardenafil hydrochloride	TABLET;ORAL	091347-003	May 3, 2012	AB	RX	No	No
Teva Pharms Usa	MORPHINE SULFATE	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	202718-001	Dec 29, 2014		DISCN	No	No
Teva Pharms	OXALIPLATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	022160-002	Aug 7, 2009	AP	RX	Yes	Yes
Teva Pharms Usa	MYCOPHENOLIC SODIUM	mycophenolic sodium	TABLET, DELAYED RELEASE;ORAL	202720-001	Oct 30, 2014		DISCN	No	No
Teva Pharms Usa	IBUPROFEN AND FAMOTIDINE	famotidine; ibuprofen	TABLET;ORAL	211278-001	Oct 29, 2021	AB	RX	No	No
Teva Pharms Usa	AMLODIPINE BESYLATE AND VALSARTAN	amlodipine besylate; valsartan	TABLET;ORAL	091235-004	Mar 30, 2015		DISCN	No	No
Teva Pharms Usa	ROSUVASTATIN CALCIUM	rosuvastatin calcium	TABLET;ORAL	079166-003	Jul 19, 2016		DISCN	No	No

Expired US Patents for Teva Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,054,430
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	8,367,605
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	9,399,025
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	6,054,430
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	7,820,203
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,342,476
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	6,620,847

Paragraph IV (Patent) Challenges for TEVA PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	for Injection	3.5 mg/vial		2016-10-26
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	for Injection	100 mcg/vial and 500 mcg/vial		2015-04-14
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Delayed-release Tablets	20 mg		2015-06-03
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	for Injection	200 mcg/vial		2015-05-01

Premature patent expirations for TEVA PHARMS

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for Teva Pharms Drugs

Country	Patent Number	Estimated Expiration
Hong Kong	1143732
Cyprus	1109799
Denmark	1443933
Cyprus	1112817
Canada	2459822
Japan	2009102408
Spain	2334774

Supplementary Protection Certificates for Teva Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	C300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
3143995	LUC00122	Luxembourg		PRODUCT NAME: EVEROLIMUS OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/09/538/001, 003, 004, 006-010 20160530
0915894	SPC/GB05/041	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB05/041 GRANTED TO GILEAD SCIENCES, INC. IN RESPECT OF THE PRODUCT COMPOSITION CONTAINING BOTH TENOFOVIR DISOPROXIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, TAUTOMER OR SOLVATE THEREOF, TOGETHER WITH EMTRICITABINE , THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6233 DATED 05/11/2008 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 23/02/2020.
0141927	97C0033	Belgium		PRODUCT NAME: PENCICLOVIR; NAT. REGISTRATION NO/DATE: 981 IS 110 F 7; 19970206; FIRST REGISTRATION: GB 10592/0078 19960228
1301519	C 2016 011	Romania		PRODUCT NAME: TENOFOVIR ALAFENAMIDA SAU O SARE SAU SOLVAT AL ACESTUIA, IN SPECIAL FUMARAT DE TENOFOVIR ALAFENAMIDA; NATIONAL AUTHORISATION NUMBER: EU/1/15/1061/001-002; DATE OF NATIONAL AUTHORISATION: 20151119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1061/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20151119
1419152	C 2012 016	Romania		PRODUCT NAME: COMBINATIE DE RILPIVIRINA SI TOATE FORMELE ECHIVALENTETERAPEUTIC ALE ACESTEIA CUM AR FI SARURILE DE ADITIE ALE RILPIVIRINEI ACCEPTABILE FARMACEUTIC, INCLUSIV SAREARILPIVIRINEI CU ACIDUL CLORHIDRIC, SI TENOFOVIR, IN PARTICULAR FUMARAT DE TENOFOVIRDISOPROXIL; NATIONAL AUTHORISATION NUMBER: EU/1/11/737/001, EU/1/11/737/002; DATE OF NATIONAL AUTHORISATION: 20111128; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/737/001, EU/1/11/737/002; DATE OF FIRST AUTHORISATION IN EEA: 20111128
2443246	2021C/538	Belgium		PRODUCT NAME: VAZKEPA - ICOSAPENT ETHYL; AUTHORISATION NUMBER AND DATE: EU/1/20/1524 20210329

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm
• Teva Pharms
• Teva Pharms Inc
• Teva Pharms Intl